References
- Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006;24:S11–25.
- Sigurdsson K. The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995. Acta Obstet Gynecol Scand. 1999;78:478–85.
- Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–65.
- Sigurdsson K, Taddeo FJ, Benediktsdottir KR, Olafsdottir K, Sigvaldason H, Oddsson K, HPV genotypes in CIN 2-3 lesions and cervical cancer: a population-based study. Int J Cancer. 2007;121:2682–7.
- Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–27.
- Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;102:3–8.
- Feoli-Fonseca JC, Oligny LL, Brochu P, Simard P, Falconi S, Yotov WV. Human papillomavirus (HPV) study of 691 pathological specimens from Quebec by PCR-direct sequencing approach. J Med Virol. 2001;63:284–92.
- Smith EM, Swarnavel S, Ritchie JM, Wang D, Haugen TH, Turek LP. Prevalence of human papillomavirus in the oral cavity/oropharynx in a large population of children and adolescents. Pediatr Infect Dis J. 2007;26:836–40.
- Icelandic Cancer Registry [homepage on the Internet]. Reykjavik: [cited 2007 Nov 1]. Available at: http://www.krabbameinsskra.is/index.jsp?id=a.
- Icelandic Cancer Society [homepage on the Internet]. Reykjavik: [cited 2007 Nov 1]. Available at: http://www.krabb.is/?PageID=39.
- Newall AT, Beutels P, Wood JG, Edmunds WJ, MacIntyre CR. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis. 2007;7:289–96.
- Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28–41.
- Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10:1915–23.
- Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604–15.
- Sundhedsstyrelsen [National Board of Health]. Copenhagen: [cited 2007 Nov 1]. Available at: http://www.sst.dk/publ/Publ2007/MTV/HPV/HPV_vaccination.pdf.
- Nasjonalt kunnskapssenteret for helsetjenesten [Norwegian Knowledge Centre for the Health Services] Oslo: [cited 2007 Nov 1]. Available at: http://www.kunnskapssenteret.no/filer/rapport_5_07_HPV_vaksiner.pdf.
- Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health. 2007;4:165–75.
- Brisson M, Van de Velde N, De Wals P, Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine. 2007;25:5399–408.
- Thiry N, Lambert MR, Cleemput I, Huybrechts M, Neyt M, Hulstaert F. HPV Vaccination for the Prevention of Cervical Cancer in Belgium: Health Technology Assessment. 2007;64C:1–134.
- Icelandic Cancer Registry [homepage on the Internet]. Reykjavik: [cited 2007 Nov 14]. Available at: http://www.krabbameinsskra.is/index.jsp?icd=C53.
- Social Insurance Administration [homepage on the Internet]. Reykjavik: [updated 2009 Jan 1; cited 2007 Nov 14]. Available at: http://eplica.tr.is/media/gjaldskrar/Komugjold_kliniskra_serfraedinga_09.pdf.
- Landspitali University Hospital [homepage on the Internet]. Reykjavik[cited 2002 Nov 14]. Available at: http://volgur.landspitali.is/GoProWeb/gpweb.nsf/htmlpages/index.html.
- Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006;24:S26–34.
- Hagstofan [Statistics Iceland]. [homepage on the Internet]. Reykjavik: [updated 2009 Apr 1; cited 2007 Nov 14]. Available at: http://www.hagstofa.is/?PageID=622&src=/temp/Dialog/varval.asp?ma=MAN00000%26ti=Lykilt%F6lur+mannfj%F6ldans+1703%2D2009+%26path=../Database/mannoldi/Yfirlit/%26lang=3%26units=Fjöldi.
- Icelandic Cancer Society [homepage on the Internet]. Reykjavik: [cited 2002 Nov 1]. Available at: http://www.krabb.is/lisalib/getfile.aspx?itemid=1520.
- Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9:37–48.
- Andrae B, Kemetli L, Sparen P, Silfverdal L, Strander B, Ryd W, Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008;100:622–9.
- Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247–55.
- Szarewski A. Prophylactic HPV vaccines. Eur J Gynaecol Oncol. 2007;28:165–9.
- Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol. 1995;33:2058–63.
- Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13:437–52.
- Baldwin JR B, Maynard JP. Insights on the Canadian Economy: Interprovincial differences in GDP per capita, labour productivity and work intensity: 1990–2003. StatCan Catalogue No. 11-624-MIE-No. 2005;011:2005.